COST-EFFECTIVENESS OF INSULIN DETEMIR IN T2DM PATIENTS POORLY CONTROLLED WITH NPH INSULIN IN POLAND

被引：0
|
作者：
Kaczor, M. P. [1 ]
Pawlik, D. [2 ]
Wojcik, R. [2 ]
Jurkiewicz, B. [3 ]
机构：
[1] Jagiellonian Univ, Coll Med, Krakow, Poland
[2] Aestimo Sc, Krakow, Poland
[3] Novo Nordisk Pharma, Warsaw, Poland
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.682
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A442 / A442
页数：1
相关论文
共 50 条
  • [1] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS NPH INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN POLAND
    Kolasa, K.
    Niewada, M.
    de Troconiz, J. Puelles Fernandez
    Townsend, R.
    McEwan, P.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A290 - A290
  • [2] Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 (T1DM) and type 2 diabetes mellitus (T2DM) in the Canadian payer setting
    Kapor, Jovana
    Minshall, Michael E.
    Tunis, Sandra L.
    Conner, Chris
    Mccormick, John
    Seager, Christine
    Groleau, Danielle
    [J]. DIABETES, 2008, 57 : A98 - A98
  • [3] Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naive Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
    Shafie, Asrul Akmal
    Ng, Chin Hui
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 333 - 343
  • [4] Cost-effectiveness of insulin detemir compared to NPH insulin for type 2 diabetes mellitus (T2DM) in the Canadian payer setting: Modeling analysis using an observational study
    Minshall, M. E.
    Tunis, S. L.
    Conner, C.
    McCormick, J., I
    Kapor, J.
    Groleau, D.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A224 - A224
  • [5] Cost-effectiveness analysis of insulin detemir compared to NPH insulin in patients with type-2 diabetes in the United Kingdom
    Smith, I
    Palmer, AJ
    Roze, S
    Kennedy-Martin, T
    [J]. VALUE IN HEALTH, 2004, 7 (06) : 735 - 736
  • [6] COST-EFFECTIVENESS CONSEQUENCES OF OBESITY IN T2DM BY INSULIN ANALOGUE THERAPY
    Jozsa, Z.
    Toth, E.
    Nagy, B.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A289 - A289
  • [7] Amelioration of glucotoxicity with insulin detemir alone or combined with premeal insulin aspart improves plasma lipoproteins, insulin secretion and hepatic steatosis in poorly controlled T2DM patients
    Cusi, K.
    Wang, S.
    Kumar, P.
    Balas, B.
    Ali, R.
    Darland, C.
    Gastaldelli, A.
    Kochunova, V.
    Peng, Q.
    Hardies, J.
    Mathew, M.
    [J]. DIABETOLOGIA, 2008, 51 : S339 - S339
  • [8] Intensive Insulin Therapy (Detemir/Aspart) Improves Nonalcoholic Fatty Liver Disease (NAFLD) in Poorly Controlled T2DM Patients
    Mathew, Manoj
    Ali, Rafeeq
    Wang, Shao
    Darland, Celia
    Kumar, Pratima
    Balas, Bogdana
    Chen, Janet
    Cusi, Kenneth
    [J]. DIABETES, 2009, 58 : A142 - A142
  • [9] Effects of insulin detemir alone, or with premeal aspart, on plasma lipoproteins, insulin secretion/action and muscle/liver fat in poorly controlled T2DM
    Wang, Shaoyun
    Kumar, Pratima
    Balas, Bogdana
    Darland, Celia
    Kochunova, Valeria
    Hardies, Jean
    Walz, Barbara
    Johnson, Lisa
    Peng, Qi
    Mathew, Manoj
    Cusi, Kenneth
    [J]. DIABETES, 2008, 57 : A572 - A572
  • [10] Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 diabetes mellitus (T1DM) in the Canadian payer setting: Modeling analysis using a randomized controlled trial
    Minshall, M. E.
    Tunis, S. L.
    Conner, C.
    McCormick, J., I
    Kapor, J.
    Groleau, D.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A223 - A224
12345